Form 4: Revolution Medicines Director Sushil Patel Executes Stock Option and Sells Shares Under 10b5-1 Plan

Director Sushil Patel of Revolution Medicines exercised stock options and sold shares on July 9, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On July 9, 2024, Sushil Patel, a director at Revolution Medicines, exercised stock options to acquire 2,155 shares of common stock at a price of $16.80.
• Simultaneously, Patel sold 2,155 shares of common stock at $44 per share.
• These transactions were executed under a 10b5-1 trading plan adopted on September 7, 2023.
• Following these transactions, Patel directly owns 19,948 shares of common stock, which includes 8,623 restricted stock units, and holds options for 32,490 shares.
• The stock options vest monthly from June 16, 2022, over a three-year period.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a routine disclosure of insider trading activity under a pre-arranged plan.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It's common for executives and directors to use 10b5-1 trading plans to sell shares over time to avoid accusations of insider trading. The exercise of options and subsequent sale can provide liquidity for the individual while aligning with company goals.

Comparison to Industry Standards

• Insider transactions are a normal part of corporate governance.
• Companies like Amgen, Gilead, and Vertex also have executives who regularly file Form 4s related to stock options and sales.
• The use of 10b5-1 plans is a standard practice to ensure compliance with insider trading regulations.

Key Dates